Bioteque (ROCO:4107) EBIT: NT$682 Mil (TTM As of Dec. 2025)


ROCO:4107 Bioteque Corp ROCO:4107
84 GF Score
Price NT$116.50
GF Value NT$129.00
Valuation Modestly Undervalued
View Full Analysis

What is Bioteque EBIT?

Bioteque ROCO:4107 +0.87% 84 EBIT is NT$682 Mil as of Dec. 2025. GuruFocus rates ROCO:4107 with a GF Score™ of 84/100 and a GF Value™ of NT$129.00 (Modestly Undervalued).

Bioteque's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$195 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$682 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioteque's annualized ROC % for the quarter that ended in Dec. 2025 was 21.76%. Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 31.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioteque's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 9.74%.


Bioteque  (ROCO:4107) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioteque's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=721.34 * ( 1 - 19.37% )/( (2687.556 + 2657.993)/ 2 )
=581.616442/2672.7745
=21.76 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4491.896 - 286.94 - ( 1517.4 - max(0, 522.802 - 2150.45+1517.4))
=2687.556

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4659.999 - 334.478 - ( 1667.528 - max(0, 546.665 - 2332.7+1667.528))
=2657.993

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioteque's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=778.644/( ( (2327.425 + max(185.281, 0)) + (2309.886 + max(197.811, 0)) )/ 2 )
=778.644/( ( 2512.706 + 2507.697 )/ 2 )
=778.644/2510.2015
=31.02 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(194.211 + 299.601 + 52.26) - (286.94 + 0 + 73.851)
=185.281

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(243.683 + 294.358 + 48.315) - (334.478 + 0 + 54.067)
=197.811

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioteque's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=682.162/7003.203
=9.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioteque EBIT Related Terms


Bioteque EBIT Historical Data

* Premium members only.

The historical data trend for Bioteque's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioteque EBIT Chart

Bioteque Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 540.09 627.50 581.12 687.74 682.16

Bioteque Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.85 172.66 136.18 178.66 194.66

ROCO:4107 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Bioteque's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioteque EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioteque's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioteque's EV-to-EBIT falls into.


ROCO:4107
84GF Score
Bioteque Corp ROCO:4107
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioteque EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$682 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$682 Mil mean?
Bioteque (ROCO:4107) has a EBIT of NT$682 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioteque.
Is Bioteque's EBIT too high?
Bioteque's current EBIT is NT$682 Mil. Overall, Bioteque has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioteque's EBIT compare to ISRG and BDX?
Bioteque's EBIT of NT$682 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioteque. Bioteque's current EBIT is NT$682 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioteque stock overvalued right now?
Based on GuruFocus' analysis, Bioteque (ROCO:4107) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$129.00, compared to a current price of NT$116.50 — trading 9.7% below its estimated fair value. The current EBIT is NT$682 Mil. Bioteque's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bioteque (ROCO:4107), the current EBIT is NT$682 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioteque (ROCO:4107) Overvalued in 2026?

Based on GuruFocus' analysis, Bioteque stock appears to be undervalued. The current stock price of NT$116.50 is trading 9.7% below its estimated GF Value™ of NT$129.00. GuruFocus considers Bioteque to be Modestly Undervalued.

Key valuation signals for ROCO:4107:

  • EBIT: NT$682 Mil
  • GF Value™: NT$129.00 vs. price of NT$116.50 (9.7% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the ROCO:4107 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioteque Business Description

Address Chang-An E. Road, 5th Floor-6, No.23, Section 1, Taipei, TWN, 104
Bioteque Corp is engaged in manufacturing, trading, and selling medical equipment and instruments. The company operates in different segments such as Manufacturing medical disposables for hemodialysis use, and selling them to dealers and retailers; Manufacturing and selling catheters for healthcare and medical PVC IV bags to medical organizations; Manufacturing and selling medical key components and inner catheters to the medical organization; and Other segment. Geographically, the company generates a majority of its revenue from Asia and the rest from North America, South America, and other regions.
84GF Score

Get the complete analysis for ROCO:4107

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$116.50
Price
NT$129.00
GF Value